Treatment options for paediatric pulmonary arterial hypertension

European Respiratory Review

Volumn 19, Issue 118, 2010, Pages 321-330

  Berger, R M F ^a   Bonnet, D ^b  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Children; Paediatric; Pulmonary arterial hypertension; Treatment algorithm

Indexed keywords

AMBRISENTAN; ANTICOAGULANT AGENT; BERAPROST; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; ILOPROST; INFLUENZA VACCINE; OXYGEN; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PNEUMOCOCCUS VACCINE; PROSTACYCLIN; PROSTANOID; SILDENAFIL; SITAXSENTAN; TADALAFIL; UNIPROST;

ABDOMINAL CRAMP; ADD ON THERAPY; AGE DISTRIBUTION; ANTICOAGULANT THERAPY; BLALOCK HANLON OPERATION; BRONCHOSPASM; CHILD; COMBINATION CHEMOTHERAPY; CONSERVATIVE TREATMENT; CONTINUOUS INFUSION; DIARRHEA; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG POTENTIATION; EISENMENGER COMPLEX; EXERCISE; FLUSHING; HEART LUNG TRANSPLANTATION; HEART SURGERY; HUMAN; INFECTION PREVENTION; INJECTION SITE PAIN; JAW DISEASE; LUNG ARTERY PRESSURE; LUNG HEMODYNAMICS; LUNG TRANSPLANTATION; LUNG VASCULAR RESISTANCE; NAUSEA; OPTIMAL DRUG DOSE; OXYGEN THERAPY; PAIN; PATIENT COMPLIANCE; PULMONARY HYPERTENSION; REVIEW; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; WALKING;

ADOLESCENT; AGE FACTORS; ANTIHYPERTENSIVE AGENTS; CHILD; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION, PULMONARY; SURVIVAL RATE; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 78650326930     PISSN: 09059180     EISSN: None     Source Type: Journal    
DOI: 10.1183/09059180.00008410     Document Type: Review

References (79)

1. Wagenvoort C, Wagenvoort N. Primary pulmonary hypertension: a pathologic study of the lung vessels in 156 clinically diagnosed cases. Circulation 1970; 42: 1163-1184.
2. Humbert M, Morrell NW, Archer SL, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43: Suppl. S, 13S-24S.
3. Rosenzweig EB, Morse JH, Knowles JA, et al. Clinical implications of determining BMPR2 mutation status in a large cohort of children and adults with pulmonary arterial hypertension. J Heart Lung Transplant 2008; 27: 668-674.
4. van Loon RL, Roofthooft MT, van Osch-Gevers M, et al. Clinical characterization of pediatric pulmonary hypertension: complex presentation and diagnosis. J Pediatr 2009; 155: 176-182.
5. Moledina S, Hislop AA, Foster H, et al. Childhood idiopathic pulmonary arterial hypertension: a national cohort study. Heart 2010; 96: 1401-1406.
6. Beghetti M, Hoeper MM, Kiely DG, et al. Safety experience with bosentan in 146 children 2-11 years old with pulmonary arterial hypertension: results from the European Postmarketing Surveillance program. Pediatr Res 2008; 64: 200-204.
7. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006; 173: 1023-1030.
8. Berger RM. Possibilities and impossibilities in the evaluation of pulmonary vascular disease in congenital heart defects. Eur Heart J 2000; 21: 17-27.
9. Haworth SG, Hislop AA. Treatment and survival in children with pulmonary arterial hypertension: The UK Pulmonary Hypertension Service for Children 2001-2006. Heart 2009; 95: 312-317.
10. Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 54: Suppl. 1, S43-S54.
11. Abman SH. Recent advances in the pathogenesis and treatment of persistent pulmonary hypertension of the newborn. Neonatology 2007; 91: 283-290.
12. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991; 115: 343-349.
13. van Loon RL, Roofthooft MT, Delhaas T, et al. Outcome of pediatric patients with pulmonary arterial hypertension in the era of new medical therapies. Am J Cardiol 2010; 106: 117-124.
14. Galiè N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009; 30: 2493-2537.
15. Bowyer JJ, Busst CM, Denison DM, et al. Effect of long term oxygen treatment at home in children with pulmonary vascular disease. Br Heart J 1986; 55: 385-390.
16. Sandoval J, Aguirre JS, Pulido T, et al. Nocturnal oxygen therapy in patients with the Eisenmenger syndrome. Am J Respir Crit Care Med 2001; 164: 1682-1687.
17. Fuster V, Steele PM, Edwards WD, et al. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 1984; 70: 580-587.
18. Donti A, Formigari R, Ragni L, et al. Pulmonary arterial hypertension in the pediatric age. J Cardiovasc Med 2007; 8: 72-77.
19. Daliento L, Somerville J, Presbitero P, et al. Eisenmenger syndrome: factors relating to deterioration and death. Eur Heart J 1998; 19: 1845-1855.
20. Ekert H, Gilchrist GS, Stanton R, et al. Hemostasis in cyanotic congenital heart disease. J Pediatr 1970; 76: 221-230.
21. Maurer HM, McCue CM, Robertson LW, et al. Correction of platelet dysfunction and bleeding in cyanotic congenital heart disease by simple red cell volume reduction. Am J Cardiol 1975; 35: 831-835.
22. Rashid A, Ivy D. Severe paediatric pulmonary hypertension: new management strategies. Arch Dis Child 2005; 90: 92-98.
23. Young G. New anticoagulants in children. Hematol Am Soc Hematol Educ Program 2008; 2008: 245-250.
24. Tulloh R, Marsh M, Blackburn M, et al. Recommendations for the use of palivizumab as prophylaxis against respiratory syncytial virus in infants with congenital cardiac disease. Cardiol Young 2003; 13: 420-423.
25. Haworth SG. The management of pulmonary hypertension in children. Arch Dis Child 2008; 93: 620-625.
26. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327: 76-81.
27. Barst RJ, Maislin G, Fishman AP. Vasodilator therapy for primary pulmonary hypertension in children. Circulation 1999; 99: 1197- 1208.
28. Sitbon O, Humbert M, Jais X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005; 111: 3105-3111.
29. Tuder RM, Cool CD, Geraci MW, et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 1999; 159: 1925-1932.
30. Christman BW, McPherson CD, Newman JH, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992; 327: 70-75.
31. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996; 334: 296-302.
32. Lammers AE, Hislop AA, Flynn Y, et al. Epoprostenol treatment in children with severe pulmonary hypertension. Heart 2007; 93: 739-743.
33. Yung D, Widlitz AC, Rosenzweig EB, et al. Outcomes in children with idiopathic pulmonary arterial hypertension. Circulation 2004; 110: 660-655.
34. Laliberte K, Arneson C, Jeffs R, et al. Pharmacokinetics and steady-state bioequivalence of treprostinil sodium (Remodulin) administered by the intravenous and subcutaneous route to normal volunteers. J Cardiovasc Pharmacol 2004; 44: 209-214.
35. Voswinckel R, Enke B, Reichenberger F, et al. Favorable effects of inhaled treprostinil in severe pulmonary hypertension: results from randomized controlled pilot studies. Ann Intern Med 2006; 144: 149-150.
36. Simonneau G, Barst RJ, Galiè N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002; 165: 800-804.
37. Oudiz RJ, Schilz RJ, Barst RJ, et al. Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. Chest 2004; 126: 420-427.
38. Tapson VF, Gomberg-Maitland M, McLaughlin VV, et al. Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial. Chest 2006; 129: 683-688.
39. Levy M, Bajolle F, Cohen S, et al. Subcutaneous treprostinil: a new therapeutic approach for idiopathic paediatric pulmonary hypertension. Eur Respir J 2009; 34: Suppl. 53, 258S.
40. Ivy DD, Claussen L, Doran A. Transition of stable pediatric patients with pulmonary arterial hypertension from intravenous epoprostenol to intravenous treprostinil. Am J Cardiol 2007; 99: 696-698.
41. McLaughlin VV, Benza RL, Rubin LJ, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol 2010; 55: 19; 15-22.
42. Fitscha P, Tiso B, Krais T, et al. Effect of iloprost on in vivo and in vitro platelet function in patients with peripheral vascular disease (PVD). Adv Prostaglandin Thromboxane Leukot Res 1987; 17A: 450-454.
43. Olschewski H, Simonneau G, Galiè N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002 1, 347: 322-329.
44. Ivy DD, Doran AK, Smith KJ, et al. Short- and long-term effects of inhaled iloprost therapy in children with pulmonary arterial hypertension. J Am Coll Cardiol 2008 15, 51: 161-169.
45. Galiè N, Humbert M, Vachiéry JL, et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2002; 39: 1496-1502.
46. Barst RJ, McGoon M, McLaughlin V, et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2003; 41: 2119-2125.
47. Gregan B, Jurgensen J, Papsdorf G, et al. Ligand-dependent differences in the internalization of endothelin A and endothelin B receptor heterodimers. J Biol Chem 2004; 279: 27679-27687.
48. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001; 358: 1119-1123.
49. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346: 896-903.
50. Galiè N, Rubin LJ, Hoeper M, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosen-tan (EARLY study): a double-blind, randomised controlled trial. Lancet 2008; 371: 2093-2100.
51. Galiè N, Beghetti M, Gatzoulis MA, et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 2006; 114: 48-54.
52. Gatzoulis MA, Beghetti M, Galiè N, et al. Longer-term bosentan therapy improves functional capacity in Eisenmenger syndrome: results of the BREATHE-5 open-label extension study. Int J Cardiol 2008; 127: 27-32.
53. Barst RJ, Ivy D, Dingemanse J, et al. Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. Clin Pharmacol Ther 2003; 73: 372-382.
54. Beghetti M, Haworth SG, Bonnet D, et al. Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: the FUTURE-1 study. Br J Clin Pharmacol 2009; 68: 948-955.
55. Rosenzweig EB, Ivy DD, Widlitz A, et al. Effects of long-term bosentan in children with pulmonary arterial hypertension. J Am Coll Cardiol 2005; 46: 697-704.
56. Simpson CM, Penny DJ, Cochrane AD, et al. Preliminary experience with bosentan as initial therapy in childhood idio-pathic pulmonary arterial hypertension. J Heart Lung Transplant 2006; 25: 469-473.
57. van Loon RL, Hoendermis ES, Duffels MG, et al. Long-term effect of bosentan in adults versus children with pulmonary arterial hypertension associated with systemic-to-pulmonary shunt: does the beneficial effect persist? Am Heart J 2007; 154: 776-782.
58. Barst RJ, Langleben D, Frost A, et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004; 169: 441-447.
59. Barst RJ, Langleben D, Badesch D, et al. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol 2006; 47: 2049-2056.
60. Benza RL, Barst RJ, Galie N, et al. Sitaxsentan for the treatment of pulmonary arterial hypertension: a 1-year, prospective, open-label observation of outcome and survival. Chest 2008; 134: 775-782.
61. Barst RJ, Rich S, Widlitz A, et al. Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: open-label pilot study. Chest 2002; 121: 1860-1868.
62. Galiè N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008; 117: 3010-3019.
63. Galié N, Badesch D, Oudiz R, et al. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2005; 46: 529-535.
64. Wharton J, Strange JW, Møller GM, et al. Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am J Respir Crit Care Med 2005; 172: 105-113.
65. Tantini B, Manes A, Fiumana E, et al. Antiproliferative effect of sildenafil on human pulmonary artery smooth muscle cells. Basic Res Cardiol 2005; 100: 131-138.
66. Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353: 2148-2157.
67. Galie N, Brundage BH, Ghofrani HA, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009; 119: 2894-2903.
68. Humpl T, Reyes JT, Holtby H, et al. Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension: twelve-month clinical trial of a single-drug, open-label, pilot study. Circulation 2005; 111: 3274-3280.
69. Barst R, Richardson H, Konourina I, et al. Oral sildenafil treatment in children with pulmonary arterial hypertension (PAH): results of a double-blind, placebo-controlled, dose-ranging study. Eur Respir J 2009; 34: Suppl. 53, 3s.
70. Stocker C, Penny DJ, Brizard CP, et al. Intravenous sildenafil and inhaled nitric oxide: a randomised trial in infants after cardiac surgery. Intensive Care Med 2003; 29: 1996-2003.
71. Schulze-Neick I, Hartenstein P, Li J, et al. Intravenous sildenafil is a potent pulmonary vasodilator in children with congenital heart disease. Circulation 2003; 108: Suppl.1, II: 167-173.
72. Akagi S, Matsubara H, Miyaji K, et al. Additional effects of bosentan in patients with idiopathic pulmonary arterial hypertension already treated with high-dose epoprostenol. Circ J 2008; 72: 114-116.
73. Simonneau G, Rubin LJ, Galiè N, et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 2008; 149: 521-530.
74. Channick RN, Olschewski H, Seeger W, et al. Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension. J Am Coll Cardiol 2006; 48: 1433-1437.
75. Hoeper MM, Markevych I, Spiekerkoetter E, et al. Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur Respir J 2005; 26: 858-863.
76. Micheletti A, Hislop AA, Lammers A, et al. Role of atrial septostomy in the treatment of children with pulmonary arterial hypertension. Heart 2006; 92: 969-972.
77. Blanc J, Vouhe P, Bonnet D. Potts shunt in patients with pulmonary hypertension. N Engl J Med 2004; 350: 623.
78. Aurora P, Edwards LB, Christie JD, et al. Registry of the International Society for Heart and Lung Transplantation: Twelfth Official Pediatric Lung and Heart/Lung Transplantation Report - 2009. J Heart Lung Transplant 2010; 28: 1129-1141.
79. Bernus A, Wagner BD, Accurso F, et al. Brain natriuretic peptide levels in managing pediatric patients with pulmonary arterial hypertension. Chest 2009; 135: 745-751.